Brinzolamide 1%/timolol 0.5%: safety and efficacy of a new fixed-combination IOP-lowering product for glaucoma.
Ingrida Januleviciene
Index: Curr. Med. Res. Opin. 26(11) , 2575-8, (2010)
Full Text: HTML
Abstract
To provide a commentary on recent studies with the new IOP-lowering fixed-combination product brinzolamide 1%/timolol 0.5%.Medline was searched for brinzolamide/timolol fixed-combination clinical literature (up to May 18, 2010) and the current comprehensive brinzolamide/timolol literature was reviewed.Compared with another carbonic anhydrase inhibitor-containing product, dorzolamide 2%/timolol 0.5%, brinzolamide/timolol has similar IOP-lowering efficacy. Brinzolamide/timolol also produces superior comfort ratings as assessed by patients who have tried both drugs - this may be explained by the more physiologic pH of brinzolamide/timolol. A recent study reported that brinzolamide/timolol was preferred over dorzolamide/timolol at a ratio of nearly 4:1 among those expressing a preference.These results demonstrate that brinzolamide/timolol is equally effective and more comfortable than dorzolamide/timolol, a fact that may positively impact patient adherence, leading to an increased likelihood of reaching target IOP goals.
Related Compounds
Related Articles:
2014-09-01
[J. Liposome Res. 24(3) , 171-81, (2014)]
2015-06-01
[Acta Ophthalmol. 93 , e261-5, (2015)]
Meta-analysis of α2-adrenergic agonists versus carbonic anhydrase inhibitors as adjunctive therapy.
2012-04-01
[Curr. Med. Res. Opin. 28(4) , 543-50, (2012)]
Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension.
2011-07-01
[Graefes Arch. Clin. Exp. Ophthalmol. 249(7) , 1065-71, (2011)]
2013-03-01
[Semin. Ophthalmol. 28(2) , 61-7, (2013)]